Download PDF
Thromb Haemost 2011; 106(05): 934-938
DOI: 10.1160/TH11-04-0273
Platelets and Blood Cells
Schattauer GmbH

Evaluating the role for the optical density in the diagnosis of heparin-induced thrombocytopenia following cardiac surgery

Chee M. Chan
1   Division of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
,
Paul J. Corso
2   Division of Cardiothoracic Surgery, Washington Hospital Center, Washington, DC, USA
,
Xiumei Sun
2   Division of Cardiothoracic Surgery, Washington Hospital Center, Washington, DC, USA
,
Peter C. Hill
2   Division of Cardiothoracic Surgery, Washington Hospital Center, Washington, DC, USA
,
Andrew F. Shorr
1   Division of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
› Author Affiliations
Further Information

Publication History

Received:27 April 2011

Accepted after major revision: 22 July 2011

Publication Date:
23 November 2017 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The poor accuracy of the enzyme immune assay (EIA) contributes to the diagnostic challenge of heparin-induced thrombocytopenia (HIT) following cardiac surgery. We sought to determine if adjusting the threshold optical density (OD) defining a positive EIA improves the test's accuracy in subjects with an OD>0.40. We retrospectively analysed the results from both EIA and confirmatory serotonin release assays (SRAs) in cardiac surgery patients with EIA OD of >0.4. Employing the SRA as the standard, we compared the area under the receiver-operating characteristic (AUROC) curves of various OD measurements for identifying HIT. We examined baseline clinical variables associated with a positive SRA in the setting of a positive HIT EIA (OD >0.4). We then used logistic regression to identify baseline clinical variables independently associated with a positive SRA given a positive EIA. The cohort included 99 subjects with positive EIAs and 35% had positive SRAs. An OD>0.40 had moderate utility as a screening test for a positive SRA (AUROC: 0.68; 95% CI: 0.55–0.80). Increasing the OD threshold did not improve the HIT EIA's screening utility. Clinical variables independently associated with a positive SRA if the EIA were positive included female gender, absence of diabetes, and use of cardiopulmonary bypass. A relatively modest elevation in the OD measurement, when it is already known to be greater than 0.4, does not reliably exclude the potential for a positive SRA in this setting.

Keywords

Heparin - optical density - screening - thrombocytopenia
 

  • References

  • 1 Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010; 24: 755-775.
    CrossrefPubMedGoogle Scholar
  • 2 Warkentin TE, Greinacher A, Koster A. et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
    CrossrefPubMedGoogle Scholar
  • 3 Pouplard C, Gueret P, Fouassier M. et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373-1379.
    CrossrefPubMedGoogle Scholar
  • 4 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-1478.
    CrossrefPubMedGoogle Scholar
  • 5 Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004; 30: 359-368.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Cuker A, Ortel TL. ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. Hematology Am Soc Hematol Educ Program. 2009: 250-252.
    Google Scholar
  • 7 Pouplard C, Leroux D, Regina S. et al. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010; 103: 145-150.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Bakchoul T, Giptner A, Bein G. et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 2011; 27: 345-348.
    PubMedGoogle Scholar
  • 9 Warkentin TE, Sheppard JI, Moore JC. et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 1304-1312.
    CrossrefPubMedGoogle Scholar
  • 10 Zwicker JI, Uhl L, Huang WY. et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.
    CrossrefPubMedGoogle Scholar
  • 11 Janatpour KA, Gosselin RC, Dager WE. et al. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol 2007; 127: 429-433.
    CrossrefPubMedGoogle Scholar
  • 12 Kim SY, Kim HK, Han KS. et al. Utility of ELISA Optical Density Values and Clinical Scores for the Diagnosis of and Thrombosis Prediction in Heparin-induced Thrombocytopenia. Korean J Lab Med 2011; 31: 1-8.
    CrossrefPubMedGoogle Scholar
  • 13 Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Tripodi A, Branchi A, Chantarangkul V. et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 2011; 31: 165-172.
    CrossrefPubMedGoogle Scholar
  • 15 Verkleij CJ, Bruijn RD, Meesters EW. et al. The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease. Clin Appl Thromb Hemost. 2010. epub ahead of print
    Google Scholar